Abstract
Dienogest (DNG) is a progestin with highly selective progesterone activity and minimal androgenic activity and is helpful in reducing endometriosis-related pain. This study assessed the long-term efficacy and safety and recurrence rate of endometrioma with DNG use beyond 12 months of treatment. A retrospective cohort study was conducted with data collected from 7 university-affiliated hospitals and included a total of 514 women with ovarian endometrioma. All patients received 2 mg of oral DNG daily for at least 48 weeks postoperatively. During continuation of DNG, the recurrence rate of ovarian endometrioma on ultrasound, adverse events, changes in menstrual pattern, and pain score (visual analogue scale) were analyzed. The average period of DNG administration in this study was 72.2 + 5.2 weeks (range: 48-164). The recurrence rate of endometrioma was 1.8% (9 of 514), and the median duration to recurrence was 58 weeks (range: 24-76). Pain was described as overall improved by 82.2% of patients; 61.6% stated the pain was “improved” and 20.6% reported “much improved.” The mean VAS score was 4.9 at baseline and significantly decreased to 2.68, 2.2, 1.6, and 2.6 at 12, 24, 48, and 96 weeks. Amenorrhea rate was 58.3% in the first 12 weeks and increased to 86.4% at 72 weeks. Prolonged daily administration of 2 mg DNG followed by surgery was associated with a lower recurrence rate of ovarian endometrioma and a reduced pain score and symptoms.
Similar content being viewed by others
References
Giudice LC, Kao LC. Endometriosis. Lancet. 2004;364(9447):1789–1799.
Ferrero S, Esposito F, Abbamonte LH, Anserini P, Remorgida V, Ragni N. Quality of sex life in women with endometriosis and deep dyspareunia. Fertil Steril. 2005;83(3):573–579.
Fourquet J, Gao X, Zavala D, et al. Patients’ report on how endo-metriosis affects health, work, and daily life. Fertil Steril. 2010;93(7):2424–2428.
Kohler G, Goretzlehner G, Rudolf K, et al. The effect of a single midcycle administration of 0.5 or 2.0 mg dienogest (17 alpha-cyanomethyl-17 beta-hydroxy-estra-4,9-dien-3-one) on pituitary and ovarian function-investigation for the use as a postcoital contraceptive. Exp Clin Endocrinol. 1984;84(3):299–304.
Jeng CJ, Chuang L, Shen J. A comparison of progestogens or oral contraceptives and gonadotropin-releasing hormone agonists for the treatment of endometriosis: a systematic review. Expert Opin Pharmacother. 2014;15(1):767–773.
Grandi G, Mueller M, Bersinger N, et al. Progestin suppressed inflammation and cell viability of tumor necrosis factor-alpha-stimulated endometriotic stromal cells. Am J Reprod Immunol. 2016;76(4):292–298.
Bizzarri N, Remorgida V, Leone Roberti Maggiore U, et al. Die-nogest in the treatment of endometriosis. Expert Opin Pharmac-other. 2014;15(13):1889–1902.
Spona J, Feichtinger W, Kindermann C, et al. A 19-norprogestin without a 17alfa-ethinyl group II: dienogest from a pharmady-namic point of view. Drugs Today. 1995;31(7):517–536.
Sasagawa S, Shimizu Y, Kami H, et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacoki-netic profile. Steroids. 2008;73(2):222–231.
Harada T, Taniguchi F. Dienogest: a new therapeutic agent for the treatment of endometriosis. Womens Health. 2010;6(1):27–35.
Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2010:(12):Cd008475.
Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Dieno-gest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010;25(3):633–641.
Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Detailed analysis of a randomized, multicenter, comparative trial of dieno-gest versus leuprolide acetate in endometriosis. Int J Gynaecol Obstet. 2012;117(3):228–233.
Harada T, Momoeda M, Taketani Y, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis-a randomized, double-blind, multicenter, controlled trial. Fertil Steril. 2009;91(3):675–681.
Park SY, Kim SH, Chae HD, Kim CH, Kang BM. Efficacy and safety of dienogest in patients with endometriosis: a single-center observational study over 12 months. Clin Exp Reprod Med. 2016;43(4):215–220.
Adachi K, Takahashi K, Nakamura K, et al. Postoperative administration of dienogest for suppressing recurrence of disease and relieving pain in subjects with ovarian endometriomas. Gynecol Endocrinol. 2016;32(8):646–649.
Takaesu Y, Nishi H, Kojima J, et al. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis. J Obstet Gynaecol Res. 2016;42(9):1152–1158.
Cho S, Jung JA, Lee Y, et al. Postoperative levonorgestrel-releasing intrauterine system versus oral contraceptives after gonadotropin-releasing hormone agonist treatment for preventing endometrioma recurrence. Acta Obstet Gyn Scan. 2014;93(1):38–44.
Lee DY, Bae DS, Yoon BK, Choi D. Post-operative cyclic oral contraceptive use after gonadotrophin-releasing hormone agonist treatment effectively prevents endometrioma recurrence. Hum Reprod. 2010;25(12):3050–3054.
Seracchioli R, Mabrouk M, Frasca C, Manuzzi L, Savelli L, Venturoli S. Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertil Steril. 2010;94(2):464–471.
Sugimoto K, Nagata C, Hayashi H, Yanagida S, Okamoto A. Use of dienogest over 53 weeks for the treatment of endometriosis. J Obstet Gynaecol Res. 2015;41(12):1921–1926.
Klipping C, Duijkers I, Remmers A, et al. Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmaco-dynamic trial of healthy women. J Clin Pharmacol. 2012;52(11):1704–1713.
Schindler AE, Christensen B, Henekel A, Oettel M, Moore C. High-dose pilot study with the novel progestogen dienogest in patients with endometriosis. Gynecol Endocrinol. 2006;22(1):9–17.
Mori T, Ito F, Matsushima H, et al. Dienogest reduces HSD17 beta 1 expression and activity in endometriosis. J Endocrinol. 2015;225(2):69–76.
Choi J, Jo M, Lee E, Lee DY, Choi D. Dienogest enhances autop-hagy induction in endometriotic cells by impairing activation of AKT, ERK1/2, and mTOR. Fertil Steril. 2015;104(3):665–664.
Kim SA, Um MJ, Kim HK, Kim SJ, Moon SJ, Jung H. Study of dienogest for dysmenorrhea and pelvic pain associated with endo-metriosis. Obstet Gynecol Sci. 2016;59(6):506–511.
Grandi G, Xholli A, Napolitano A, Palma F, Cagnacci A. Pelvic pain and quality of life of women with endometriosis during quadriphasic estradiol valerate/dienogest oral contraceptive: a patient-preference prospective 24-week pilot study. Reprod Sci. 2015;22(5):626–632.
Strowitzki T, Faustmann T, Gerlinger C, Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol. 2010;151(2):193–198.
Petraglia F, Hornung D, Seitz C, et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet. 2012;285(1):167–173.
Momoeda M, Harada T, Terakawa N, et al. Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res. 2009;35(6):1069–1076.
Gerlinger C, Faustmann T, Hassall JJ, Seitz C. Treatment of endometriosis in different ethnic populations: a meta-analysis of two clinical trials. BMC Womens Health. 2012;12:9.
Finkelstein JS, Lee MLT, Sowers M, et al. Ethnic variation in bone density in premenopausal and early perimenopausal women: Effects of anthropometric and lifestyle factors. J Clin Endocr Metab. 2002;87(7):3057–3067.
Seeman E. Estrogen, androgen, and the pathogenesis of bone fragility in women and men. Curr Osteoporos Rep. 2004;2(3):90–96.
Popat VB, Calis KA, Vanderhoof VH, et al. Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab. 2009;94(7):2277–2283.
Guerriero S, Mais V, Ajossa S, et al. The role of endovaginal ultrasound in differentiating endometriomas from other ovarian cysts. Clin Exp Obstet Gynecol. 1995;22(1):20–22.
Van Holsbeke C, Van Calster B, Guerriero S, et al. Endometriomas: their ultrasound characteristics. Ultrasound Obstet Gynecol. 2010;35(6):730–740.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Lee, S.R., Yi, K.W., Song, J.Y. et al. Efficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma. Reprod. Sci. 25, 341–346 (2018). https://doi.org/10.1177/1933719117725820
Published:
Issue Date:
DOI: https://doi.org/10.1177/1933719117725820